|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/13/21 Advanced Biomedical Techs Inc. 10-Q 7/31/21 37:2.3M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 512K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 18K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 18K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 13K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 13K
12: R1 Cover HTML 63K
13: R2 Condensed Consolidated Balance Sheets HTML 112K
14: R3 Condensed Consolidated Balance Sheets HTML 21K
(Parenthetical)
15: R4 Condensed Consolidated Statements of Operations HTML 128K
and Comprehensive Loss (Unaudited)
16: R5 Condensed Consolidated Statements of Stockholders' HTML 69K
Deficit (Unaudited)
17: R6 Condensed Consolidated Statements of Cash Flows HTML 98K
(Unaudited)
18: R7 Basis of Presentation HTML 18K
19: R8 Organization HTML 33K
20: R9 Principles of Consolidation HTML 17K
21: R10 Use of Estimates HTML 15K
22: R11 Related Party Transactions HTML 27K
23: R12 Commitments and Contingencies HTML 24K
24: R13 Fair Value of Financial Instruments HTML 17K
25: R14 Recent Accounting Pronouncements HTML 16K
26: R15 Going Concern HTML 18K
27: R16 Commitments and Contingencies (Tables) HTML 20K
28: R17 Organization (Details Narrative) HTML 53K
29: R18 Principles of Consolidation (Details Narrative) HTML 20K
30: R19 Related Party Transactions (Details Narrative) HTML 41K
31: R20 Schedule of Future Minimum Lease Obligations of HTML 31K
Operating Leases (Details)
32: R21 Commitments and Contingencies (Details Narrative) HTML 18K
33: R22 Going Concern (Details Narrative) HTML 32K
35: XML IDEA XML File -- Filing Summary XML 55K
11: XML XBRL Instance -- form10-q_htm XML 442K
34: EXCEL IDEA Workbook of Financial Reports XLSX 33K
7: EX-101.CAL XBRL Calculations -- abmt-20210731_cal XML 115K
8: EX-101.DEF XBRL Definitions -- abmt-20210731_def XML 123K
9: EX-101.LAB XBRL Labels -- abmt-20210731_lab XML 498K
10: EX-101.PRE XBRL Presentations -- abmt-20210731_pre XML 326K
6: EX-101.SCH XBRL Schema -- abmt-20210731 XSD 66K
36: JSON XBRL Instance as JSON Data -- MetaLinks 174± 230K
37: ZIP XBRL Zipped Folder -- 0001493152-21-022511-xbrl Zip 92K
Exhibit 31.1
SARBANES-OXLEY SECTION 302(a) CERTIFICATION
I, Hui Wang, certify that:
| 1. | I have reviewed this 10-Q for the three and nine months ended July 31, 2021 of Advanced BioMedical Technologies, Inc; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
| b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
| c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
| d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and | |
| b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| Date: September 13, 2021 | /s/ Hui Wang |
| Hui Wang, Director and Chief Executive Officer |
C:
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 9/13/21 | None on these Dates | ||
| For Period end: | 7/31/21 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/16/07 Advanced Biomedical Techs Inc. SB-2 1/12/07 9:787K Law Office of Con… PS/FA |